<DOC>
	<DOCNO>NCT01424930</DOCNO>
	<brief_summary>The purpose study establish safety profile oral ( mouth ) abiraterone acetate oral prednisone follow short-term administration standardize low-fat high-fat meal patient metastatic ( spread ) castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>A Study Determine Short-Term Safety Continuous Dosing Abiraterone Acetate Prednisone Modified Fasting Fed States Patients With Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This multicenter , open-label study 24 ( total 28 ) men ass short-term safety oral abiraterone acetate 1 g oral prednisone 5 mg twice daily administer modify fasted state meal various fat content . All patient take daily abiraterone acetate first 7 day modify fasted state ( food 2 hour 1 hour dose ) . In Cohort 1 , 6 evaluable patient take abiraterone acetate daily 7 day standardize low-fat meal Cycle 1 Day 8 Cycle 1 Day 14 ; , Cohort 2 , 6 evaluable patient take abiraterone acetate daily 7 day standardize high-fat meal Cycle 1 Day 8 Cycle 1 Day 14 . All patient continue take abiraterone acetate daily modify fasted state start Cycle 1 Day 15 disease progression . Toxicity related dose low-fat high-fat meal define Grade 3 high AEs special interest ; Grade 3 high serious adverse event ( SAEs ) occur food safety evaluation period . Cohort 2 may expand total 18 evaluable patient deem safe . Decisions regard escalation cohort expansion cohort make study evaluation team . Pharmacokinetic evaluation cohort perform Cycle 1 Days 7 14 predose multiple timepoints postdose 24 hour ; Cycle 1 Days 8 11 2 hour follow abiraterone acetate dose administration . Abiraterone acetate , 1 g ( four 250-mg tablet ) orally ( take mouth ) daily . Patients may take abiraterone acetate progression clinical disease . Prednisone , 5 mg , orally , twice day .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Adenocarcinoma prostate Metastatic disease document bone , compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan Surgical medical castration testosterone less 50 ng/dL ( &lt; 2.0 nM ) Prostatespecific antigen ( PSA ) radiographic progression document assessment specify study protocol Platelets &gt; 100,000/Âµl Hemoglobin &gt; =9.0 g/dL Liver function test ( LFTs ) : Serum bilirubin &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ; Eastern Cooperative Oncology Group ( ECOG ) status score &lt; =2 Small cell carcinoma prostate Known brain metastasis , chronic liver disease elevate LFTs Prior cytotoxic chemotherapy metastatic prostate cancer Treatment prostate cancer within 30 day Day 1 Cycle 1 surgery , radiation , chemotherapy immunotherapy Use investigational drug within 30 day Day 1 Cycle 1 current enrollment investigational drug device study Recent history ischemic heart disease , Electrocardiogram ( ECG ) abnormalities atrial fibrillation Active infection medical condition would make prednisone ( corticosteroid ) use contraindicate Chronic medical condition require high dose corticosteroid prednisone 5 mg twice daily</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Metastatic castration-resistant prostate cancer</keyword>
	<keyword>CRPC</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Food Safety</keyword>
</DOC>